Top Markets
Coin of the day
Neuropathix, Inc. Neuropathix, Inc.

Neuropathix, Inc.

NPTX
Rank in Stocks #41303
Neuropathix, Inc. is a biopharmaceutical firm dedicated to identifying,... Neuropathix, Inc. is a biopharmaceutical firm dedicated to identifying, advancing, and bringing to market innovative treatments derived from its exclusive platform of synthetic cannabinoid derivatives. The company's efforts are concentrated on the research and preclinical development of chemical compounds like KLS-13019, KLS-13023, and KLS-13022, alongside associated molecules and synthetic cannabidiol-based therapies. These investigational drugs are being explored for their potential application in treating various conditions, including chemotherapy-induced peripheral neuropathy, overt hepatic encephalopathy, mild traumatic brain injury, and chronic traumatic encephalopathy. Previously operating as Kannalife, Inc., the organization rebranded as Neuropathix, Inc. in November 2020. Established in 2010, Neuropathix, Inc. maintains its headquarters in Doylestown, Pennsylvania.
Share Price
$0.0003
Last synced: 2023-06-13
Market Cap
$28.14K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Neuropathix, Inc. (NPTX)

Category

P/B ratio for Neuropathix, Inc. (NPTX)
P/B ratio as of 2026 TTM: 0
According to Neuropathix, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Neuropathix, Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE